Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...
The American Journal of Managed Care

Gene Therapy Well Tolerated in Wet AMD, Shows Promise in Visual Acuity

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...
GEN

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...
Nasdaq

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
WPRI 12

Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally ...